At Kiniksa, we focus on cultivating a highly skilled and passionate team determined to deliver the promise of transformative therapies to patients who need them most.
Sanj K. Patel
Sanj is the CEO and Chairman of the Board of Kiniksa Pharmaceuticals, which is focused on developing and commercializing therapies for patients with devastating diseases and unmet medical needs.
He brings more than 25 years of experience in the biopharmaceutical industry and has a combination of scientific, clinical, and commercial skills. He took Kiniksa public on the NASDAQ Global Market in May 2018. Sanj previously created Synageva in 2008 to focus on rare diseases and designed and initiated its lead program, (Kanuma®) for lysosomal acid lipase deficiency (LAL-D), in July 2008. Kanuma was approved globally in 2015 as the first therapy for patients suffering from this devastating, often terminal disease. He took Synageva public on the NASDAQ Global Market in November 2011 and raised over $1 billion in capital in less than 5 years. In June 2015, Synageva was sold to Alexion Pharmaceuticals for $9.5B (including cash), which represented the highest premium ever paid for a biotech company valued over $5B. Prior to founding Synageva, Sanj was an executive at Genzyme Corporation (1999–2008), where he was head of US sales, marketing, and commercial operations for the Genzyme Therapeutics franchise, and led the US launch of Myozyme® in addition to holding sales and marketing responsibility for Cerezyme®, Fabrazyme®, and Aldurazyme®. Previously, he held several cross-functional senior leadership roles at Genzyme, including as Vice President, Clinical Research and as Head of the Global Clinical Research Operations Council for all Genzyme divisions, including therapeutics, oncology, and transplant. He was responsible for clinical operations for all Genzyme products and was instrumental in the path to commercialization of several treatments. Notably, Sanj led the Fabrazyme® clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, he held senior roles in clinical research and commercial operations at Burroughs Wellcome, Hoechst Marrion Roussel, and Fujisawa/Otsuka Pharmaceuticals. Sanj obtained his BSc with Honors in biotechnology from the University of the South Bank, London. He successfully completed his management and business studies at Ealing College, London, and his pharmacology research program at the Wellcome Foundation. He has dedicated much of his career and philanthropy to rare diseases, such as sarcoma, immunological diseases, and genetic inborn errors of metabolism, including diseases closely linked to Ashkenazi Jewish populations and other ethnic groups.
Sanj is the founder and director of the Sanj K. Patel and Family Foundation, a philanthropic organization founded in 2015 which supports various charities focused on patients with rare and devastating diseases, including the Sarcoma Foundation of America.
Ross is Kiniksa’s Group Vice President & General Manager of the rilonacept franchise.
Ross joined the Kiniksa team in 2019 and brings over 18 years’ experience in biopharmaceuticals, having led sales, marketing and diagnostic functions within orphan and ultra-orphan disease fields. Prior to joining Kiniksa, Ross played a lead role towards the successful commercialization efforts for innovative cell and gene therapies at Novartis Gene Therapies and Spark Therapeutics. Additionally, Ross served as the metabolic franchise commercial lead at Alexion following the acquisition of Synageva, where he was General Manager, UK & Ireland. Ross holds a first-class BA (Honors) degree from Middlesex University Business School in London.
Melissa serves as the head of Human Resources at Kiniksa.
She brings over 15 years of experience in human resources strategy and operations, primarily focused in the life sciences industry. Most recently, Melissa served as global HR business partner at Alexion and was responsible for driving human resources strategy to support the research and development organization. Prior to joining Alexion, Melissa served as the director of human resources at Synageva, where she was responsible for leading human resources operations. Previously, Melissa held roles of increasing responsibility at Alkermes and AMAG Pharmaceuticals and before that held various human resources and operations positions. She has extensive experience in all aspects of global human resources, including talent acquisition, organizational development, compensation, benefits, and leadership development. Melissa holds a bachelor’s degree in business management from Keene State College in New Hampshire.
Mark is our Chief Financial Officer.
He joined Kiniksa prior to the company’s initial public offering in 2018. Mark is responsible for establishing and expanding Kiniksa’s relationships with its global investor base and industry analysts through communicating the company’s business principles, corporate strategy, and financial performance. He also provides input on corporate communications, financial operations, and other shareholder-related activities. Mark joined Kiniksa from Ironwood Pharmaceuticals, where he was a member of the investor relations team. Prior to Ironwood, Mark was a vice president in the equities division at Goldman Sachs, where he built strategic relationships with key hedge fund and mutual fund companies and helped raise capital for private and public companies. Mark also held roles of increasing responsibility within the equities divisions of Morgan Stanley and Bank of America Securities. Mark has over 20 years of experience in the financial services and life sciences industries. He has a strong understanding of institutional investor needs as well as an extensive knowledge of finance and equity markets.
Mark holds a BA in government and history from Bowdoin College and is a Chartered Financial Analyst.
Martina serves as Senior Vice President of Regulatory Affairs at Kiniksa.
She brings over 25 years of global regulatory affairs experience (US, Europe, and Japan/Asia) across all stages of drug development, with biologics and small molecules in a variety of therapeutic areas such as metabolism, cardiovascular, oncology, and neuroscience. She has led the successful submission and approval processes of many regulatory filings, including multiple original New Drug Applications/Marketing Authorization Applications, and numerous Investigational New Drug Applications and Clinical Trial Applications, many of which resulted in life cycle management extensions for new indications and dosage forms (Lenvima®, Halaven®, Fycompa®, Banzel®, Exelon®, Comtan®, Stalevo®). Martina has broad experience in rare diseases and orphan drugs, including regulatory submissions that resulted in Breakthrough Therapy designation and/or Fast Track designation. Martina was most recently the head of global regulatory affairs at Eisai Inc., where she was instrumental in building a global regulatory affairs group and leading regulatory filings, including priority and accelerated approvals in the US, EU, and Japan. Martina previously held regulatory positions of increasing responsibility at Novartis AG in both Switzerland and the US. She started her regulatory career as a group leader at the Swiss Health Authority (Swissmedic). Martina has a PhD in biochemistry from the Swiss Federal Institute of Technology (ETH) in Zurich, Switzerland.
Maddy is our General Counsel.
Maddy joined Kiniksa prior to the company’s first commercial drug launch and has over 18 years of legal experience in the life science industry. Before Kiniksa, Maddy was Vice President, Legal and Corporate Secretary at Verastem Oncology where she provided strategic advice and legal support for all domestic commercial operations and alliance management with international business partners. Prior to Verastem, Maddy was Vice President, Associate General Counsel at NxStage Medical where she was responsible for drafting and negotiating a broad range of contracts and reviewing product marketing materials. Before NxStage, Maddy started her career as a transactional attorney in the life sciences group of Ropes & Gray LLP in Boston, Massachusetts. Maddy received her JD degree from the University of California, Berkeley and a BS in Biology from Duke University.
John is Kiniksa’s Chief Medical Officer.
His over 25 years of experience spans from basic biological/medical science through all phases of clinical development and regulatory strategy for small molecules and biologics. He was most recently clinical research head of the Cardiovascular and Metabolic Diseases Research Unit at Pfizer Inc., where he was responsible for bringing forward programs in diabetes, heart failure, lipids, and metabolic liver disease from preclinical through early clinical development and proof of concept. John previously served as Chief Medical Officer of Cerenis Therapeutics in France, a publicly traded company on the Euronext exchange. He was responsible for designing and executing clinical trials and regulatory strategy for a portfolio of products relating to HDL and reverse lipid transport and also played an instrumental role in the company’s capital-raising efforts, including its initial public offering. Before moving to France, John was Global Clinical Leader at Bayer HealthCare Pharma, where he was responsible for the Phase III program, NDA filing, and launch of Xarelto® in atrial fibrillation as well as Xarelto Life Cycle Management. He started in the pharmaceutical industry at Merck & Co., Inc., in cardiovascular clinical research and clinical pharmacology, leading programs in thrombosis and dyslipidemia that spanned the early- and late-stage portfolio, including Zocor® and Aggrastat®, the Vytorin®, Zetia®, and Tredaptive® clinical development programs and NDAs, as well as in-licensing activities in cardiovascular disease. John obtained an MD, PhD from Duke University, where his PhD work focused on the protein chemistry of immune mediators. He subsequently completed a residency in internal medicine and a fellowship in cardiovascular medicine at the Brigham and Women’s Hospital, including a postdoctoral fellowship at the Massachusetts Institute of Technology researching the role of inflammatory mediators in vascular disease and restenosis. He received Board certification in internal medicine and cardiology and is a Fellow of the American College of Cardiology. He was a member of the clinical faculty at the University of Pennsylvania as a clinical associate and served as an attending physician for 10 years, precepting cardiology fellows in the HUP outpatient cardiology clinic. John has authored more than 75 peer-reviewed journal articles and abstracts. He received a bachelor of arts, summa cum laude, and a bachelor of science, summa cum laude, from Tulane University.
Eben serves as Kiniksa’s Chief Business Officer and has extensive experience in long-range strategic planning, forecasting, decision analysis, business development, licensing, valuation, and new product strategy.
Before Kiniksa, he was Senior Director and Head of Business Development at Synageva BioPharma. Prior to that he was Director, Business and Corporate Development for Civitas Therapeutics. There he played a lead role in managing the company through a dual-path IPO process which led, ultimately, to a successful acquisition by Acorda Therapeutics. Before joining Civitas, he worked in a variety of roles with increasing responsibility at Vertex Pharmaceuticals, Zalicus, and EPIX Pharmaceuticals. Eben holds a BS in behavior neuroscience from Northeastern, an MS in biomedical engineering from Boston University and both a JD and MBA from Suffolk University.
Arian has served as Kiniksa’s Senior Vice President of Clinical Development since joining in November of 2019.
Arian has an extensive background in research and development across a variety of pharma companies, with a focus on cardiovascular, metabolic rare diseases and, lately, inflammation and fibrosis. Previously, he served as SVP of clinical development for Galapagos NV, while concurrently serving as the US country head and global head of safety. He was previously head of clinical development at Elpidera, a subsidiary of Moderna, where he was responsible for all aspects of clinical development for rare diseases. Before this, Arian held the position of VP, head of rare disease therapeutic area, at Dicerna Pharmaceuticals, Inc. Arian was also global clinical development lead, clinical research and development, at Shire Human Genetic Therapies, Inc., and prior to that was medical director at Pfizer and Acusphere Inc. Earlier in his career, he worked on medical devices/microsphere technology for cardiovascular applications at Acusphere Inc. Arian holds an MD degree from University of Tirana, Albania, and an MPH in healthcare management from Harvard’s School of Public Health, Boston, MA.
Mei is the Vice President of Technical Operations at Kiniksa.
She has extensive experience in all phases of process development, GMP manufacturing and overall CMC strategy. She oversees the process development and GMP manufacturing of drug substance and drug product, analytical development, quality control, and supply chain logistics. Mei joined Kiniksa in 2018 and was promoted to vice president of CMC in 2020. Before joining Kiniksa, Mei was the head of biologics downstream process development and manufacturing and the CMC program lead at Tesaro (now part of GSK). Prior to Tesaro, Mei held positions of increasing responsibilities and the CMC lead role for multiple programs at Shire (now part of Takeda). Mei holds a doctor of philosophy degree in biochemistry from the Ohio State University.
Mike is our Vice President of Finance and Chief Accounting Officer, with responsibility for finance, treasury, and tax.
He has over 20 years of experience in financial management and operations, primarily focused on the life sciences industry. Prior to joining Kiniksa, Mike spent over six years at LFB USA Inc., formerly rEVO Biologics, Inc., in roles of financial and operational leadership, most recently serving as senior vice president of finance and accounting. He played a key role in the financial carve-out of rEVO Biologics to create a focused commercial entity to finance a follow-on indication of the company’s previously approved biologic product, ATryn®. At LFB USA, his most recent responsibilities included financial operations, human resources, information technology, and program management. Prior to LFB USA, he held senior financial management positions at BioSphere Medical, Inc., a publicly traded medical device company. Mike began his career in public accounting, including at PricewaterhouseCoopers, where he worked with a variety of public and private audit clients. He has a Bachelor of Business Administration in accounting from Siena College. Mike is also a Certified Public Accountant.
Lora is Kiniksa’s Executive Director and Head of Global Patient Advocacy & Engagement.
She brings over 15 years of experience working in biotech and social services. Most recently, Lora was Senior Director, Marketing at Sobi, where she was responsible for leading the cross-functional brand strategy and US launch of Gamifant®. Before joining Sobi, Lora served as Director and Interim Head, Global Patient Advocacy at Alnylam overseeing a global team responsible for advocacy relations and patient engagement across multiple clinical and commercial-stage RNAi therapeutics. Prior to Alnylam, Lora held several roles of increasing leadership responsibility in the areas of rare disease marketing, commercial operations, and patient services at Genzyme. Lora started her career as a social worker with the Commonwealth of Massachusetts. She currently serves on the board of directors for the MassBioEd Foundation. Lora received her BA in psychology from the University of Rochester and completed the Strategic Marketing Management Executive Education Program at the University of Chicago Booth School of Business.
Dina serves as Vice President of Quality here at Kiniksa.
She brings over 25 years of global quality experience in the areas of biologics, RNAi therapeutics, small molecules, medical devices, and combination products. She has significant breadth of experience across all stages of the product lifecycle, including treatments for rare diseases and orphan drugs.
Prior to joining us at Kiniksa, Dina held quality leadership roles at Eli Lilly, Alnylam Pharmaceuticals, Instrumentation Laboratory, Pfizer, Parker Hannifin, and Avid Technology. Throughout her career, she has led inspection readiness activities, been a champion for capability-building across all quality assurance programs and systems, and has been instrumental in multiple FDA and EMA approvals.
Dina holds a Master of Science degree in business management from Merrimack College, and is a certified Lean Six-Sigma Black Belt and a Project Management Professional (PMP).
Rasmus has driven strategy across Kiniksa since the inception of the company in 2015.
He brings to Kiniksa 20 years of life-science business leadership experience. At Synageva, he led the transformation of the technical operations organization and site setup since the IPO in 2011. He also drove corporate strategic analysis and cross-functional breakthrough initiatives. Prior to Synageva, from 2008 to 2011, he led the successful turnaround of the global commercial organization of the GN Group, a global leader in audiology. From 1996 to 2008, Rasmus worked for Novo Nordisk in Denmark, USA, Brazil, and Mexico, where he held increasing positions within general management (30+ countries), finance, investor relations and R&D portfolio management. Rasmus received an MSc in economics from the University of Copenhagen and has completed executive training at Harvard Business School, Stanford University, and INSEAD.
Chad is our Vice President, Chief Compliance Officer, and also serves as our Data Protection Officer.
Before Kiniksa, Chad was Vice President, Chief Compliance Officer for bluebird bio, Inc., where he was responsible for establishing the global compliance & ethics and privacy programs. Prior to joining bluebird bio, Chad was the head of compliance at ARIAD Pharmaceuticals, Inc., where he was responsible for all aspects of compliance through their acquisition by Takeda Pharmaceutical Company. Before ARIAD, Chad was with Cubist Pharmaceuticals, where he served in several roles of increasing leadership responsibility until their acquisition by Merck & Co., Inc. Chad started his life science career at Boston Scientific Corporation in compliance operations. He is a graduate of The Citadel, Babson College’s F. W. Olin School of Business, and a veteran of the US Navy. He also serves on the editorial board for Policy & Medicine Compliance Update.
Board of Directors
Dr. Baker is a Co-Managing Member of Baker Bros. Advisors, LP, registered investment advisor focused on long-term investments in life science companies. Dr. Baker and his brother, Julian Baker, started their fund management careers in 1994 when they co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker currently serves on the Board of Directors at Alexion Pharmaceuticals, Genomic Health, Inc., and Seattle Genetics, Inc. and previously served on the Board of Directors at Synageva BioPharma Corp. and Ardea Bioscience, Inc. Dr. Baker holds a Bachelor of Science and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.
Dr. Biggar is a partner at Baker Bros. Advisors, LP, a registered investment advisor focused on long-term investments in life science companies. Dr. Biggar joined Baker Bros. Advisors LP in 2000. Dr. Biggar is currently Chairman of the board of directors of ACADIA Pharmaceuticals and serves on the board of Vivelix Pharmaceuticals, Ltd. Dr. Biggar also served as a director for Synageva BioPharma Corp. Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester.
G. Bradley Cole
He served as Executive Advisor of Exact Sciences Corporation (“Exact Sciences”) since April 2020, and from November 2019 until April 2020 he served as its GM, Precision Oncology. Prior to that, Mr. Cole served as Chief Financial Officer of Genomic Health, Inc. (“Genomic Health”), a molecular diagnostics company, from July 2014 to November 2019 and from July 2004 to January 2011, and as Chief Operating Officer of Genomic Health from January 2009 until March 2018, which was acquired by Exact Sciences. Mr. Cole served as Secretary of Genomic Health from February 2005 until July 2012. From December 1997 to May 2004, he served in various roles at Guidant Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for the Endovascular Solutions Group. From January 2001 until May 2004 he served as Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant Corporation. Previously, Mr. Cole served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company. Mr. Cole currently serves on the board of directors of Castle Biosciences, a skin cancer diagnostics company, and as Vice Chairman of the Board of Trustees of Biola University. Mr. Cole holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University.
Dr. Levy is a Director on the Boards of Madrigal Pharmaceuticals, Aquinox Pharmaceuticals, and Kodiak Sciences, all publicly traded biopharmaceutical companies. Previously he was Executive Vice President, Chief Drug Development and Medical Officer at Incyte Corporation between 2013 and 2016. At Incyte, he was responsible for the clinical development and registration of Jakafi® (ruxolitinib) as well as an expanding clinical development portfolio in Oncology and Inflammation. Dr. Levy has more than 27 years of experience in the pharmaceutical and biotechnology sectors through his prior positions at Celgene, DuPont Pharmaceuticals and Sandoz / Novartis. Dr. Levy has extensive clinical research, regulatory and product development skills and has worked in multiple therapeutic areas. Dr. Levy received his A.B. from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
Mr. Malley is the President of Mossrock Capital, LLC, a private investment firm in Denver, Colorado, since May 2007. Mr. Malley worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund, and also led the Janus Healthcare team of analysts. From 1991 to 1998 Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley serves on the board of directors of BeiGene, Ltd. and Kura Oncology, Inc. both which are publicly-traded biotechnology companies. In the past, he served on the boards of OvaScience, Inc., Cougar Biotechnology, Puma Biotechnology and Synageva BioPharma Corp., all publicly-traded biotechnology companies. Mr. Malley holds a B.S. degree in Biology from Stanford University.
Previously, Ms. McCain served as Senior Vice President and Head of Legal of Sanofi Genzyme, a global business unit of Sanofi, from January 2016 to September 2, 2016. Ms. McCain held roles of increasing responsibility after joining Genzyme Corporation (“Genzyme”) in May 1997, including becoming its General Counsel after Genzyme was acquired by Sanofi in 2011. Prior to joining Genzyme, Ms. McCain was an associate at the law firm Palmer & Dodge LLP where her practice focused on general corporate and securities law matters. Ms. McCain holds a B.A. from the University of Pennsylvania with a major in political science and a J.D. from Columbia University School of Law.
Sanj K. Patel
He brings more than 25 years of experience in the Biopharmaceutical industry and has a combination of scientific, clinical and commercial skills. He took Kiniksa public on the NASDAQ Global Market in May 2018. Sanj previously created Synageva in 2008 to focus on rare diseases and designed and initiated its lead program (Kanuma®) for Lysosomal Acid Lipase Deficiency (LAL Deficiency) in July 2008. Kanuma was approved globally in 2015 as the first therapy for patients suffering from this devastating, often terminal disease. He took Synageva public on the NASDAQ Global Market in November 2011 and raised over $1 billion in capital in less than 5 years. In June 2015, Synageva was sold to Alexion Pharmaceuticals for $9.5B (including cash), which represented the highest premium ever paid for a biotech company valued over $5B. Prior to Synageva, Sanj was an executive at Genzyme Corporation (1999-2008) where he was head of U.S. Sales, Marketing and Commercial Operations for the Genzyme Therapeutics franchise, and led the U.S. launch of Myozyme®, in addition to sales and marketing responsibility for Cerezyme®, Fabrazyme® and Aldurazyme®. Previously, he held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council for all Genzyme divisions, including Therapeutics, Oncology and Transplant. He was responsible for clinical operations for all Genzyme products and was instrumental in the path to commercialization of several treatments. Notably, Sanj led the Fabrazyme® clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, he held senior roles in clinical research and commercial operations at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa/Otsuka Pharmaceuticals. Sanj obtained his BSc with Honors in Biotechnology from the University of the South Bank, London. He successfully completed his management and business studies at Ealing College, London and his Pharmacology research program at the Wellcome Foundation. He has dedicated much of his career and philanthropy to rare diseases, such as Sarcoma, Immunological diseases, and genetic inborn errors of metabolism, including diseases closely linked to Ashkenazi Jewish populations and other ethnic groups.
Sanj is the founder and director of the Sanj K. Patel and Family Foundation, a philanthropic organization founded in 2015 which supports various charities focused on patients with rare and devastating diseases, including the Sarcoma Foundation of America.
Ms. Popovits served as the Chief Executive Officer of Genomic Health from 2009-2020, and served as the chairman of the board of directors of Genomic Health from 2012-2020. Ms. Popovits also serves on the board of directors of MyoKardia, Inc., and previously served on the board of directors of ZS Pharma Inc. Ms. Popovits holds a B.A in Business from Michigan State University.
Barry D. Quart
Dr. Quart has served as a director of Heron Therapeutics, Inc. since June 2012 and was appointed Chief Executive Officer of Heron in May 2013. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through May 2013 and as a director through its acquisition by AstraZeneca PLC in June 2012. Previously, he was with Pfizer, Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from June 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in June 2015. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.